Reneo Pharmaceuticals, Inc. (RPHM) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Irvine, CA, United States. The current CEO is Gregory J. Flesher.
RPHM has IPO date of 2021-04-08, 8 full-time employees, listed on the NASDAQ Global Market, a market capitalization of $60.84M.
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
